MAXIMUM ANDROGEN BLOCKADE USING LHRH AGONIST BUSERELIN IN COMBINATIONWITH SHORT-TERM (2 WEEKS) OR LONG-TERM (CONTINUOUS) CYPROTERONE-ACETATE IS NOT SUPERIOR TO STANDARD ANDROGEN DEPRIVATION IN THE TREATMENT OF ADVANCED PROSTATE-CANCER - FINAL ANALYSIS OF EORTC GU GROUP TRIAL-30843
Hj. Devoogt et al., MAXIMUM ANDROGEN BLOCKADE USING LHRH AGONIST BUSERELIN IN COMBINATIONWITH SHORT-TERM (2 WEEKS) OR LONG-TERM (CONTINUOUS) CYPROTERONE-ACETATE IS NOT SUPERIOR TO STANDARD ANDROGEN DEPRIVATION IN THE TREATMENT OF ADVANCED PROSTATE-CANCER - FINAL ANALYSIS OF EORTC GU GROUP TRIAL-30843, European urology, 33(2), 1998, pp. 152-158
This is the final analysis of EORTC GU Group Trial 30843 in which the
treatment of advanced, metastatic prostate cancer with a combination o
f the LHRH agonist buserelin (nasal spray) and cyproterone acetate (An
drocur), either continuously of only during the first 2 weeks, was com
pared with orchidectomy, There was no significant difference between t
he three arms as far as response rate, time to progression (subjective
and objective) and duration of survival are concerned, Retrospective
stratification according to the most important prognostic factors did
not change the conclusions, Possible reasons for the difference with t
rial 30853, which used the same entry criteria but compared goserelin
and flutamide with orchidectomy, are discussed, Reasons for using cypr
oterone acetate in combination treatment are the prevention of flare o
f the disease after LHRH agonists only and the prevention/reduction of
toxicity in the form of hot flushes.